Skip to main content

Table 3 Extent of mono- and combination drug therapy use in the male LUTS (including OAB) sub-cohort

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

Monotherapy N % of monotherapy patients % of all patients in male OAB sub-cohort % of all male patients
Any OAB drug monotherapy 7946 100.0 64.2 16.3
Any antimuscarinic monotherapy 7443 93.7 60.1 15.3
Solifenacin 2759 34.7 22.3 5.7
Oxybutynin 2613 32.9 21.1 5.4
Tolterodine 1445 18.2 11.7 3.0
Mirabegron 503 6.3 4.1 1.0
Fesoterodine 285 3.6 2.3 0.6
Trospium 227 2.9 1.8 0.5
Flavoxate 49 0.6 0.4 0.1
Darifenacin 47 0.6 0.4 0.1
Propiverine 18 0.2 0.1 0.04
Combination drug therapy N % of combination drug therapy patients % of all patients in male OAB sub-cohort % of all male patients
Any combination drug therapy 4437 100.0 35.8 9.1
Any BPO drug + any OAB drug 3863 87.1 31.2 7.9
Any BPO drug + any antimuscarinic 3643 82.1 29.4 7.5
Any BPO drug + mirabegron 347 7.8 2.8 0.7
Any alpha-blocker + any OAB drug (± 5-ARI) 3538 79.7 28.6 7.3
Any alpha-blocker + any antimuscarinic (± mirabegron and/or 5-ARI) 3330 75.1 26.9 6.8
Any alpha-blocker + mirabegron (± antimuscarinic and/or 5-ARI) 326 7.3 2.6 0.7
Triple drug therapy (any alpha-blocker + any 5-ARI + any OAB drug) 958 21.6 7.7 2.0
Any OAB drug + any 5-ARI (± alpha-blocker) 1284 28.9 10.4 2.6
Any OAB drug + any 5-ARI (excl. alpha-blocker) 325 7.3 2.6 0.7
Mirabegron + any antimuscarinic (± BPO drug) 307 6.9 2.5 0.6
Any ≥ 2 OAB (± BPO drug) 964 21.7 7.8 2.0
Any ≥ 2 OAB (no BPO drug) 574 12.9 4.6 1.2
Any ≥ 2 antimuscarinics (± BPO drug and/or mirabegron) 666 15.0 5.4 1.4
Solifenacin + tamsulosin 902 20.3 7.3 1.9
Oxybutynin + tamsulosin 364 8.2 2.9 0.7
Tamsulosin + tolterodine 248 5.6 2.0 0.5
Finasteride + solifenacin + tamsulosin 233 5.3 1.9 0.5
Doxazosin + solifenacin 114 2.6 0.9 0.2
Solifenacin + tolterodine 114 2.6 0.9 0.2
Finasteride + oxybutynin + tamsulosin 111 2.5 0.9 0.2
Oxybutynin + solifenacin 102 2.3 0.8 0.2
Finasteride + solifenacin 96 2.2 0.8 0.2
Mirabegron + tamsulosin 96 2.2 0.8 0.2
Doxazosin + oxybutynin 95 2.1 0.8 0.2
Mirabegron + solifenacin 95 2.1 0.8 0.2
Fesoterodine + tamsulosin 83 1.9 0.7 0.2
Dutasteride + solifenacin + tamsulosin 79 1.8 0.6 0.2
Doxazosin + tolterodine 69 1.6 0.6 0.1
Other combinations 1636 36.9 13.2 3.4
Drug class N % of all patients in male OAB sub-cohort % of all male patients
Any OAB drug 12,383 100 25.4
Any OAB drug (no BPO drug) 8520 68.8 17.5
Any antimuscarinic 11,653 94.1 23.9
Total mirabegron 1039 8.4 2.1
Any alpha-blocker 3538 28.6 7.3
Any 5-ARI 1284 10.4 2.6
  1. 5-ARI: 5-alpha reductase inhibitor; BPO: benign prostatic obstruction; LUTS: lower urinary tract symptoms; OAB: overactive bladder